Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Show More...
-
Website https://www.ionispharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 28.95 EUR
-
Last Updated 29-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.62 -0.85 -0.65 -0.55 -0.33 -0.74 -0.5 0.15 2.07 2.08 1.11 Dividends USD Payout Ratio % * Shares Mil 99.0 100.0 101.0 111.0 118.0 120.0 121.0 126.0 134.0 143.0 142.0 Book Value Per Share * EUR 1.93 1.44 1.27 2.51 2.4 1.87 1.09 2.06 4.5 8.52 8.86 Free Cash Flow Per Share * EUR -0.68 -0.99 -0.48 0.68 -0.61 0.88 -1.05 0.63 3.23 0.96 Return on Assets % -10.14 -16.38 -12.71 -8.71 -4.32 -9.23 -9.26 0.86 13.88 10.05 5.53 Financial Leverage (Average) 2.25 2.83 2.99 2.24 3.71 4.76 9.16 4.0 2.55 2.2 2.27 Return on Equity % -22.84 -40.77 -36.97 -21.61 -12.26 -38.5 -57.64 4.49 40.16 23.54 12.76 Return on Invested Capital % -15.53 -19.13 -11.73 -8.43 -3.48 -9.48 -9.23 5.27 23.51 17.16 10.38 Interest Coverage -3.62 -4.07 -2.53 -2.44 -1.45 -1.39 -1.16 0.48 -0.7 8.11 4.39 Current Ratio 4.56 4.73 5.7 7.52 7.25 5.62 5.96 5.2 7.87 9.97 9.91 Quick Ratio 4.47 4.61 5.5 7.36 7.06 5.48 5.8 4.83 7.48 9.39 9.35 Debt/Equity 0.61 1.26 1.21 0.6 1.76 2.35 5.9 1.83 0.6 0.53 0.58